Business UpdateAug 10, 2026, 12:09 PM
Helus Pharma CEO to Speak at Canaccord Genuity Conference
AI Summary
Helus Pharma announced that CEO Michael Halstead will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The clinical-stage pharmaceutical company is focused on developing novel serotonergic agonists (NSAs) for mental health conditions. Its pipeline includes HLP003 in Phase 3 for major depressive disorder with Breakthrough Therapy Designation, and HLP004 in Phase 2 for generalized anxiety disorder.
Key Highlights
- Helus Pharma CEO Michael Halstead to speak at Canaccord Genuity conference.
- Fireside chat scheduled for August 12, 2026, at 12:00 p.m. EDT.
- Webcast of the fireside chat will be available live and for replay.
- Company is developing novel serotonergic agonists (NSAs) for mental health conditions.
- HLP003 is in Phase 3 for major depressive disorder, with Breakthrough Therapy Designation.
- HLP004 is in Phase 2 for generalized anxiety disorder.
- Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland.
Price Impact
More from HELP